Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its fiscal third-quarter results later this week. Market watchers are predicting strong growth driven by the strong demand of Lilly's blockbuster drugs, particularly its insulin portfolio. However, there are also concerns about potential challen